[Form 4] Inspire Medical Systems, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Inspire Medical Systems, Inc. (INSP) director Myriam J. Curet, M.D. reported several small transactions in the company’s common stock on a Form 4. The filing shows open‑market purchases and sales between $77.2754 and $163.8388 per share, leaving her with 3,365 shares of common stock held directly after the last reported transaction on 08/08/2025.

The filing explains that some trades occurred inadvertently through a pooled investment vehicle that did not filter out Inspire’s securities. It also notes that a May 8, 2025 sale of 1 share at $153.2237 was matchable under Section 16(b) with a prior April 7, 2025 purchase of 1 share at $148.262. Dr. Curet paid the company $4.97, representing the full short‑swing profit from that transaction.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Curet Myriam

(Last) (First) (Middle)

C/O INSPIRE MEDICAL SYSTEMS, INC.

5500 WAYZATA BLVD., SUITE 1600

(Street)

GOLDEN VALLEY MN 55416

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/20/2025		P(1)		4	A	$163.8388	3,370	D
Common Stock	04/07/2025		P(1)		1	A	$148.262	3,371	D
Common Stock	05/08/2025		S(1)		2(2)	D	$153.2237	3,369	D
Common Stock	08/08/2025		S(1)		4	D	$77.2754	3,365	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These transactions occurred inadvertently through holdings in a pooled investment vehicle that did not filter out the Issuer's securities.

2. The Reporting Person's sale of common stock on May 8, 2025 were matchable under Section 16(b) of the Securities Exchange Act of 1934, as amended, to the extent of 1 share at a price per share of $153.2237, with the Reporting Person's purchase of 1 share of common stock at a price per share of $148.262 on April 7, 2025. Dr. Curet paid to the Issuer $4.97, representing the full amount of the profit realized in connection with the short-swing transaction.

	/s/ Bryan Phillips, Attorney-in-Fact for Myriam J. Curet, M.D.	11/24/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What does the INSP Form 4 filed by Myriam J. Curet report?

The Form 4 reports that Inspire Medical Systems, Inc. (INSP) director Myriam J. Curet, M.D. bought and sold small amounts of the company’s common stock in 2025, and discloses her updated direct ownership of 3,365 shares after the last reported trade.

What stock transactions did the INSP director report on this Form 4?

The filing lists multiple common stock trades, including purchases at prices such as $163.8388 on 03/20/2025 and $148.262 on 04/07/2025, and sales at prices such as $153.2237 on 05/08/2025 and $77.2754 on 08/08/2025.

Why does the INSP Form 4 mention a pooled investment vehicle?

The explanation states that some transactions occurred inadvertently through holdings in a pooled investment vehicle that did not filter out Inspire Medical Systems’ securities, leading to the reported trades in the issuer’s stock.

What is the Section 16(b) short-swing profit issue disclosed for INSP?

The filing notes that the director’s May 8, 2025 sale of 1 share at $153.2237 was matchable under Section 16(b) with an April 7, 2025 purchase of 1 share at $148.262, creating a short‑swing profit.

How much short-swing profit did the INSP director repay to the company?

The director, Dr. Curet, paid $4.97 to Inspire Medical Systems, Inc., which the filing describes as the full amount of the profit realized from the matchable short‑swing transaction under Section 16(b).

What is the director’s ownership in INSP after the reported transactions?

After the final reported trade on 08/08/2025, the Form 4 shows that the director beneficially owns 3,365 shares of Inspire Medical Systems common stock, held directly.